Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease

Parkinson’s disease (PD) is associated with increased iron levels in the substantia nigra (SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to chelate iron from various brain regions and improve PD symptomology. In a randomised double-blind, placebo controll...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Sci Rep
Päätekijät: Martin-Bastida, Antonio, Ward, Roberta J., Newbould, Rexford, Piccini, Paola, Sharp, David, Kabba, Christina, Patel, Maneesh C., Spino, Michael, Connelly, John, Tricta, Fernando, Crichton, Robert R., Dexter, David T.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5431100/
https://ncbi.nlm.nih.gov/pubmed/28469157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-01402-2
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia